Hepatitis B is a disease that has not been clinically cured until now, a problem that has plagued infectious disease doctors and hepatologists for many years. With the emergence of oral antiviral drugs in more than 30 years of work, long-term and persistent use of drugs can inhibit the replication of the hepatitis B virus, and therefore can greatly slow down the progression of liver disease and reduce the risk of liver fibrosis, cirrhosis and hepatocellular carcinoma. In the past 10 years, injectable interferon has also been used in the field of hepatitis B antiviral treatment, and the clinical goal pursued has evolved from “DNA conversion” to “e antigen conversion”. Recently, China’s 12th Five-Year Plan even boldly put forward the idea of “clinical cure for hepatitis B”. Under the high attention of the Ministry of Health, a series of treatment processes for hepatitis B have emerged, among which individualized treatment is of great interest to patients. RGT (Response Guide Therapy) is shown in the following figure: The development of a phased treatment plan based on the response of different people in the treatment is conducive to achieving better clinical benefits for each patient.